ClinicalTrials.gg
CompletedNCT04300296PRELUDEUpdated Aug 22, 2023Results posted

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

A Phase 2 interventional study of secukinumab 300 mg Q4W and secukinumab 300 mg Q2W in Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris, sponsored by Novartis Pharmaceuticals. Completed at 35 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Lichen Planus with a site in United States — 6 open to participants now, 7 under way, 1 of them phase 3. Lichen Planus · United States.

Enrollment
5th of 26
111 · median 20
Started
2020
with 1 other
Phase 2
17 of 33
3 open now
Registered
18th of 33
by date
Lead sponsor
2 of 33
Novartis Pharmaceuticals

Among the 33 studies in Lichen Planus with a site in United States, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2020, is one of 17 in phase 2, and was the 18th registered.

Lichen Planus

75 studies on the registry are indexed under Lichen Planus; 16 are open to participants now.

Browse Lichen Planus studies →

Open to participants now

6 of the 33 studies in Lichen Planus with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Lichen Planus studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Lichen Planus with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.

Read the detailed description

This was a 32-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial which assessed the efficacy and safety of secukinumab 300 mg in two different dosing regimens: every 4 weeks (Q4W) and every 2 weeks (Q2W) in approximately 111 patients with biopsy-proven forms of lichen planus.

There was a screening period (up to 4 weeks prior to baseline), a treatment period 1 (baseline to Week 16), a treatment period 2 (Week 16 to Week 32) and a follow-up period (8 weeks after Week 32).

03

Conditions studied

  • Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Browse trials for

Keywords

  • Lichen planus
  • CLP
  • MLP
  • LPP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Female and male patients ≥ 18 years of age.
  3. Subjects must have -confirmed forms of cutaneous lichen planus (CLP), mucosal lichen planus (MLP), or active lichen planopilaris (LPP) eligible for systemic therapy based on the following criteria:

    • rated IGA of ≥ 3 (moderate or severe) AND
    • inadequate response to topical of high-ultrahigh potency in the opinion of the investigator.
  4. If using any of the allowed topical treatments on the affected areas, the dose and application frequency should remain stable for 2 weeks prior to randomization and until Week 16.

Exclusion criteria

Exclusion Criteria:

  1. Clinical history suspicious for lichenoid drug eruption.
  2. Lichen planus pigmentosus.
  3. Clinical picture or history suspicious of paraneoplastic mucosal lichen planus.
  4. Subjects whose lichen planus is a predominantly bullous variant.
  5. Mucosal LP of the oral cavity or gastrointestinal involvement requiring the patient to use parenteral nutrition or feeding tube.
  6. Clinical picture of scarring alopecia without active inflammation.
  7. Clinical picture of burnt-out cicatricial alopecia (alopecia of Brocque).
  8. Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP
  9. Clinical picture of LPP in patients who have already failed 3 or more systemic or immunomodulatory agents (e.g. systemic , hydroxychloroquine, cyclosporine, methotrexate and mycophenolate mofetil).
  10. Currently enrolled in any other clinical trial involving any agent or device.
  11. Previous exposure to any other biologic drug directly targeting IL-17A or IL-17RA (e.g. secukinumab, ixekizumab or brodalumab) or IL-23/p19 (e.g. tildrakizumab, guselkumab, risankizumab).
  12. Diagnosis of active infectious diseases of the skin, scalp or mucosa (for example bacterial, viral or fungal infections of the mouth) that may interfere with the assessment of the study disease or require treatment with prohibited medications.
  13. Diagnosis of active inflammatory diseases of the skin, scalp or mucosa other than lichen planus that may interfere with the assessment of the study disease or require treatment with prohibited medications.
  14. Presence of any other skin condition that may affect the evaluations of the study disease.
  15. Underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) and/or presence of laboratory abnormalities which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
  16. Current, severe, progressive or uncontrolled diseases that render the patient unsuitable for the trial, including any medical or psychiatric condition that, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Cutaneous lichen planus secukinumab 300mg Q4W

    Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in cutaneous lichen planus patients

    Drug: secukinumab 300 mg Q4W

  • Placebo comparator
    Cutaneous lichen planus placebo

    Placebo in 1ml PFS in cutaneous lichen patients

    Other: Placebo

  • Experimental
    Mucosal lichen planus secukinumab 300 mg Q4W

    Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in mucosal lichen planus patients.

    Drug: secukinumab 300 mg Q4W

  • Placebo comparator
    Mucosal lichen planus placebo

    Placebo 1 ml PFS in mucosal lichen planus patients

    Other: Placebo

  • Experimental
    Lichen planopilaris secukinumab 300 mg Q4W

    Secukinumab 300 mg every 4weeks provided in pre-filled syringe in lichen planopilaris patients.

    Drug: secukinumab 300 mg Q4W

  • Placebo comparator
    Lichen planopilaris placebo

    Placebo in 1ml PFS in lichen planopilaris patients

    Other: Placebo

  • Experimental
    Cutaneous lichen planus placebo to secukinumab 300 mg Q2W

    Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2

    Drug: secukinumab 300 mg Q2W

  • Experimental
    Mucosal lichen planus placebo to secukinumab 300 mg Q2W

    Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2

    Drug: secukinumab 300 mg Q2W

  • Experimental
    Lichen planopilaris placebo to secukinumab 300 mg Q2W

    Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2

    Drug: secukinumab 300 mg Q2W

Interventions

  • secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.

    Also known as: AIN457

  • secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.

    Also known as: AIN457

  • OtherPlacebo

    Matching placebo administered via a pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP

    Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.

    Time frame: Baseline up to week 16

Secondary outcomes

  1. Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

    Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  2. Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

    Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  3. Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

    Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  4. Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

    The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=\<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=\>50% of total body surface

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  5. Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

    The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  6. Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  7. Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

  8. Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

    Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

    Time frame: Baseline, Week 16 and Week 32

  9. Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

    Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

    Time frame: Baseline, Week 16 and Week 32

  10. Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

    Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

    Time frame: Baseline, Week 16 and Week 32

  11. Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

    Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

    Time frame: Baseline, Week 16 and Week 32

  12. Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

    Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

    Time frame: Baseline, Week 16 and Week 32

  13. Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

    Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

    Time frame: Baseline, Week 16 and Week 32

  14. Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

    REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease.

    Time frame: Baseline, Week 16 and Week 32

  15. Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

    OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity.

    Time frame: Baseline, Week 16 and Week 32

  16. Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

    The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity

    Time frame: Baseline, Week 16 and Week 32

  17. Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

    Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life.

    Time frame: Baseline, Week 16 and Week 32

07

Results

Posted Aug 22, 2023

Participant flow

Treatment Period 1: Baseline to 16 Weeks
Participant flow — Treatment Period 1: Baseline to 16 Weeks
MilestoneAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP CohortAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP CohortAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Started251224132413
Placebo responder010100
Completed231024132312
Not completed220011
Withdrew: Progressive disease100000
Withdrew: Adverse event000010
Withdrew: Subject/guardian decision120001
Treatment Period 2: 16 to 32 Weeks
Participant flow — Treatment Period 2: 16 to 32 Weeks
MilestoneAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP CohortAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP CohortAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Started22823112312
Completed17719101712
Not completed514160
Withdrew: Adverse event102010
Withdrew: Progressive disease201020
Withdrew: Protocol deviation010000
Withdrew: Subject/guardian decision201130

Outcome measures

PrimaryResponse Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP

Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.

Time frame:
Baseline up to week 16
Reported as:
Median · percentage of participants
Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP
percentage of participantsAIN457 300 mg Q4W - TP 1 - CLP CohortPlacebo - TP 1 - CLP CohortAIN457 300 mg Q4W - TP 1 - MLP CohortPlacebo - TP 1 - MLP CohortAIN457 300 mg Q4W - TP 1 - LPP CohortPlacebo - TP 1 - LPP Cohort
Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP44.0 (25.8 to 63.32)58.2 (31.0 to 82.6)37.5 (20.3 to 57.2)23.1 (6.5 to 49.2)37.6 (20.2 to 57.3)30.9 (10.8 to 57.6)
Statistical analysis
  • AIN457 300 mg Q4W - TP 1 - CLP Cohort vs Placebo - TP 1 - CLP Cohort · Posterior median difference: -13.9 · 95% CI -44.8 to 19.3Bayesian model to obtain the posterior distribution of the treatment difference between AIN457 and placebo
  • AIN457 300 mg Q4W - TP 1 - MLP Cohort vs Placebo - TP 1 - MLP Cohort · Posterior median difference: 14.1 · 95% CI -17.0 to 40.7Bayesian model to obtain the posterior distribution of the treatment difference between AIN457 and placebo
  • AIN457 300 mg Q4W - TP 1 - LPP Cohort vs Placebo - TP 1 - LPP Cohort · Posterior median difference: 6.5 · 95% CI -25.4 to 35.4Bayesian model to obtain the posterior distribution of the treatment difference between AIN457 and placebo
SecondaryNumber (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo - TP 1 - CLP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Week 2 IGA <=2 n=25,12,051—
Week 2 IGA improvement >=2 n=25,12,020—
Week 2 IGA 0/1 n=25,12,020—
Week 4 IGA <=2 n=24,11,092—
Week 4 IGA improvement. >=2 n=24,11,030—
Week 4 IGA 0/1 n=24,11,020—
Week 8 IGA <=2 n=25,11,0103—
Week 8 IGA improvement. >=2 n=25,11,041—
Week 8 IGA 0/1 n=25,11,031—
Week 12 IGA <=2 n=25,12,0104—
Week 12 IGA improvement. >=2 n=25,12,032—
Week 12 IGA 0/1 n=25,12,041—
Week16 IGA <=2 n=25,12,101175
Week 16 IGA improvement. >=2 n=25,12,10431
Week 16 IGA 0/1 n=25,12,10420
Week 20 IGA <=2 n=24,0,1011—1
Week 20 IGA improvement. >=2 n=24,0,105—1
Week 20 IGA 0/1 n=24,0,105—1
Week 24 IGA <=2 n=25,0,1014—3
Week 24 IGA improvement. >=2 n=25,0,1010—2
Week 24 IGA 0/1 n=25,0,1010—1
Week 28 IGA <=2 n=23,0,1012—4
Week 28 IGA improvement. >=2 n=23,0,107—1
Week 28 IGA 0/1 n=23,0,106—1
Week 32 IGA <=2 n=24,0,99—2
Week 32 IGA improvement. >=2 n=24,0,97—2
Week 32 IGA 0/1 n=24,0,96—1
SecondaryNumber (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Week 2 IGA <=2 n=24,12,053—
Week 2 IGA improvement >=2 n=24,12,011—
Week 2 IGA 0/1 n=24,12,011—
Week 4 IGA <=2 n=24,13,042—
Week 4 IGA improvement. >=2 n=24,13,011—
Week 4 IGA 0/1 n=24,13,011—
Week 8 IGA <=2 n=24,13,053—
Week 8 IGA improvement. >=2 n=24,13,002—
Week 8 IGA 0/1 n=24,13,001—
Week 12 IGA <=2 n=24,13,054—
Week 12 IGA improvement. >=2 n=24,13,054—
Week 12 IGA 0/1 n=24,13,042—
Week16 IGA <=2 n=24,13,11931
Week 16 IGA improvement. >=2 n=24,13,11531
Week 16 IGA 0/1 n=24,13,11420
Week 20 IGA <=2 n=24,0,1110—3
Week 20 IGA improvement. >=2 n=24,0,115—2
Week 20 IGA 0/1 n=24,0,115—1
Week 24 IGA <=2 n=24,0,1010—4
Week 24 IGA improvement. >=2 n=24,0,103—2
Week 24 IGA 0/1 n=24,0,103—0
Week 28 IGA <=2 n=23,0,117—4
Week 28 IGA improvement. >=2 n=23,0,111—3
Week 28 IGA 0/1 n=23,0,111—0
Week 32 IGA <=2 n=23,0,109—2
Week 32 IGA improvement. >=2 n=23,0,102—1
Week 32 IGA 0/1 n=23,0,102—0
SecondaryNumber (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W - TP 2- LPP Cohort
Week 2 IGA <=2 n=24,13,041—
Week 2 IGA improvement >=2 n=24,13,010—
Week 2 IGA 0/1 n=24,13,010—
Week 4 IGA <=2 n=24,13,092—
Week 4 IGA improvement. >=2 n=24,13,021—
Week 4 IGA 0/1 n=24,13,021—
Week 8 IGA <=2 n=24,13,083—
Week 8 IGA improvement. >=2 n=24,13,031—
Week 8 IGA 0/1 n=24,13,031—
Week 12 IGA <=2 n=24,13,084—
Week 12 IGA improvement. >=2 n=24,13,032—
Week 12 IGA 0/1 n=24,13,022—
Week16 IGA <=2 n=24,13,13944
Week 16 IGA improvement. >=2 n=24,13,13300
Week 16 IGA 0/1 n=24,13,13200
Week 20 IGA <=2 n=24,0,1310—6
Week 20 IGA improvement. >=2 n=24,0,136—1
Week 20 IGA 0/1 n=24,0,134—0
Week 24 IGA <=2 n=23,0,1310—8
Week 24 IGA improvement. >=2 n=23,0,137—3
Week 24 IGA 0/1 n=23,0,136—2
Week 28 IGA <=2 n=24,0,1310—9
Week 28 IGA improvement. >=2 n=24,0,136—4
Week 28 IGA 0/1 n=24,0,135—3
Week 32 IGA <=2 n==24,0,1111—7
Week 32 IGA improvement. >=2 n==24,0,115—5
Week 32 IGA 0/1 n==24,0,114—4
SecondaryNumber (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=\<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=\>50% of total body surface

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo - TP 1 - CLP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Baseline 0 Score00—
Baseline 1 score30—
Baseline 2 score60—
Baseline 3 score63—
Baseline 4 score56—
Baseline 5 score53—
Week 2 0 score000
Week 2 1 score60—
Week 2 2 score51—
Week 2 3 score93—
Week 2 4 score35—
Week 2 5 score23—
Week 4 0 score00—
Week 4 1 score30—
Week 4 2 score80—
Week 4 3 score83—
Week 4 4 score35—
Week 4 5 score23—
Week 8 0 score00—
Week 8 1 score71—
Week 8 2 score51—
Week 8 3 score72—
Week 8 4 score44—
Week 8 5 score23—
Week 12 0 score00—
Week 12 1 score61—
Week 12 2 score72—
Week 12 3 score70—
Week 12 4 score37—
Week 12 5 score22—
Week 16 0 score000
Week 16 1 score420
Week 16 2 score1233
Week 16 3 score533
Week 16 4 score244
Week 16 5 score200
Week 20 0 score0—0
Week 20 1 score6—0
Week 20 2 score12—3
Week 20 3 score3—2
Week 20 4 score1—3
Week 20 5 score2—2
Week 24 0 score1—0
Week 24 1 score8—0
Week 24 2 score10—2
Week 24 3 score1—2
Week 24 4 score2—4
Week 24 5 score3—2
Week 28 0 score0—0
Week 28 1 score6—0
Week 28 2 score11—2
Week 28 3 score1—3
Week 28 4 score3—3
Week 28 5 score2—2
Week 32 0 score2—0
Week 32 1 score5—1
Week 32 2 score10—0
Week 32 3 score3—4
Week 32 4 score1—2
Week 32 5 score3—2
SecondaryNumber (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo - TP 1 - CLP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Baseline n=25,12,000—
Week 4 n=24,11,020—
Week 8 n=25,11,020—
Week 12 n=25,12,031—
Week 16 n=25,12,10322
Week 20 n=24,0,103—1
Week 24 n=25,0,104—1
Week 28 n=23,0,103—1
Week 32 n=25,0,92—1
SecondaryNumber (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2- MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Baseline n=24,13,000—
Week 4 n=24,13,021—
Week 8 n=24,13,041—
Week 12 n=24,13,042—
Week 16 n=24,13,11532
Week 20 n=24,0,117—2
Week 24 n=24,0,107—3
Week 28 n=23,0,113—2
Week 32 n=23,0,104—2
SecondaryNumber (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Count of participants · Participants
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
ParticipantsAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W TP 2 - LPP Cohort
Baseline n=24,13,000—
Week 4 n=24,13,031—
Week 8 n=24,13,031—
Week 12 n=24,13,022—
Week 16 n=24,13,13211
Week 20 n=24,0,134—3
Week 24 n=23,0,132—3
Week 28 n=24,0,132—2
Week 32 n=24,0,111—3
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo - TP 1 - CLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - CLP Cohort
Baseline - Question 15.1 ± 2.665.7 ± 2.775.8 ± 3.01
Week 16 Severity of itch during past 24 hours n=25,12,10-0.8 ± 1.91-2.3 ± 3.25-2.0 ± 3.53
Week 32 Severity of itch during past 24 hours n=25,0,9-1.5 ± 2.24—-1.1 ± 2.42
Baseline- Question 25.6 ± 2.726.3 ± 2.865.9 ± 3.03
Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10-0.9 ± 2.52-2.7 ± 3.73-1.9 ± 3.54
Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9-1.3 ± 2.13—-1.2 ± 2.49
Baseline- Question 34.8 ± 3.086.1 ± 2.946.1 ± 3.21
Week 16 How bothered by Itch during past 24 hours n=25,12,10-1.0 ± 2.65-2.7 ± 3.55-2.4 ± 3.84
Week 32 How bothered by Itch during past 24 hours n=25,0,9-1.1 ± 2.45—-1.2 ± 2.28
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Baseline - Question 1 n=23,13,112.5 ± 2.833.8 ± 3.814.3 ± 3.93
Week 16 Severity of itch during past 24 hours n=23,13,110.3 ± 3.26-0.2 ± 3.41-0.3 ± 3.72
Week 32 Severity of itch during past 24 hours n=22,0,100.1 ± 2.97—-0.4 ± 3.37
Baseline - Question 2 n=23,13,112.4 ± 2.903.6 ± 3.994.1 ± 4.16
Week 16 How severe was itch at worst moment during past 24 hours n=23,13,110.8 ± 3.040.4 ± 3.250.4 ± 3.56
Week 32 How severe was itch at worst moment during past 24 hours n=22,0,100.3 ± 2.43—0.4 ± 3.81
Baseline - Question 3 n=24,13,113.4 ± 3.414.0 ± 4.144.5 ± 4.27
Week 16 How bothered by Itch during past 24 hours n=23,13,11-0.5 ± 2.950.1 ± 3.120.0 ± 3.41
Week 32 How bothered by Itch during past 24 hours n=22,0,10-0.2 ± 1.33—-0.4 ± 4.25
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Baseline - Question 1 n=24,13,134.5 ± 2.253.8 ± 2.683.8 ± 2.68
Week 16 Severity of itch during past 24 hours n=24,13,11-0.5 ± 2.25-1.1 ± 2.47-1.1 ± 2.47
Week 32 Severity of itch during past 24 hours n=24,0,11-1.6 ± 2.06—-2.4 ± 2.84
Baseline - Question 2 n=24,13,135.1 ± 2.434.2 ± 2.864.1 ± 4.16
Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13-0.7 ± 2.35-1.3 ± 2.81-1.3 ± 2.81
Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11-1.8 ± 2.23—-2.6 ± 3.01
Baseline - Question 3 n=24,13,114.0 ± 2.363.2 ± 2.793.2 ± 2.79
Week 16 How bothered by Itch during past 24 hours n=24,13,13-0.4 ± 2.43-1.2 ± 3.02-1.2 ± 3.02
Week 32 How bothered by Itch during past 24 hours n=24,0,11-1.7 ± 2.08—-2.2 ± 2.44
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - CLP CohortPlacebo - TP 1 - CLP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort
Baseline - Question 1 n=25,12,101.09 ± 2.053.4 ± 2.613.5 ± 2.51
Week 16 Severity of pain during past 24 hours n=25,12,100.2 ± 1.48-0.8 ± 1.40-0.8 ± 1.48
Week 32 Severity of pain during past 24 hours n=25,0,9-0.3 ± 1.65—-0.3 ± 2.29
Baseline - Question 2 n=25,12,102.2 ± 2.483.9 ± 3.233.9 ± 3.03
Week 16 How severe was pain at worst moment during past 24 hours n=25,12,100.1 ± 2.03-1.2 ± 1.70-1.0 ± 1.56
Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9-0.4 ± 2.35—-0.4 ± 2.70
Baseline - Question 3 n=25,12,102.1 ± 2.553.7 ± 2.963.8 ± 2.94
Week 16 How bothered by pain during past 24 hour n=25,12,100.1 ± 2.09-0.6 ± 1.620.5 ± 1.72
Week 32 How bothered by pain during past 24 hours n=25, 0,9-0.2 ± 1.71—-0.3 ± 2.45
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Baseline - Question 1 n=24,13,115.1 ± 2.865.9 ± 3.096.3 ± 3.23
Week 16 Severity of pain during past 24 hours n=24,13,11-0.5 ± 3.08-0.1 ± 3.010.0 ± 3.29
Week 32 Severity of pain during past 24 hours n=23,0,10-0.3 ± 2.18—-0.6 ± 2.59
Baseline - Question 2 n=24,13,115.4 ± 2.996.4 ± 3.156.7 ± 3.26
Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11-0.5 ± 3.13-0.3 ± 2.75-0.2 ± 2.99
Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10-0.3 ± 2.06—-0.5 ± 2.46
Baseline - Question 3 n=24,13,115.5 ± 3.356.5 ± 2.766.8 ± 2.79
Week 16 How bothered by pain during past 24 hour n=24,13,11-0.8 ± 3.54-0.3 ± 2.21-0.1 ± 2.34
Week 32 How bothered by pain during past 24 hours n=23,0,10-0.5 ± 2.74—-0.9 ± 2.69
SecondarySummary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Baseline - Question 1 n=24,13,122.5 ± 2.432.0 ± 2.382.0 ± 2.38
Week 16 Severity of pain during past 24 hours n=24,13,120.3 ± 2.61-0.5 ± 1.90-0.5 ± 1.90
Week 32 Severity of pain during past 24 hours n=24,0,11-0.6 ± 1.72—-1.5 ± 2.02
Baseline - Question 2 24,13,122.8 ± 2.682.5 ± 2.732.5 ± 2.73
Week 16 How severe was pain at worst moment during past 24 hours n=24,13,120.2 ± 3.16-0.9 ± 2.25-0.9 ± 2.25
Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11-0.8 ± 2.06—-2.0 ± 2.45
Baseline - Question 3 n=24,13,122.7 ± 2.562.4 ± 2.752.4 ± 2.75
Week 16 How bothered by pain during past 24 hour n=24,13,120.0 ± 2.87-1.1 ± 2.25-1.1 ± 2.25
Week 32 How bothered by pain during past 24 hours n=24,0,11-0.8 ± 1.79—-1.9 ± 2.51
SecondarySummary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease.

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Baseline n=21,12,1021.31 ± 8.74725.29 ± 9.10226.95 ± 8.855
Week 16 n=21,12,10-4.83 ± 11.102-5.79 ± 14.476-4.10 ± 15.196
Week 32 n=20,0,9-6.08 ± 10.206—-2.17 ± 15.802
SecondarySummary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity.

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - MLP CohortPlacebo - TP 1 - MLP CohortPlacebo to AIN457 300 mg Q2W TP 2 - MLP Cohort
Baseline n=21,12,1011.0 ± 5.9813.4 ± 5.5013.9 ± 5.78
Week 16 n=21,12,10-1.0 ± 6.820.8 ± 6.47-0.4 ± 7.09
Week 32 n=20,0,9-1.8 ± 5.67—-0.7 ± 7.00
SecondarySummary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 - LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort
Baseline n=24,13,135.92 ± 2.0715.95 ± 1.7675.95 ± 1.767
Week 16 n=24,13,13-1.44 ± 2.517-2.24 ± 2.522-2.24 ± 2.522
Week 32 n=24,0,13-2.44 ± 2.428—-3.20 ± 2.927
SecondarySummary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life.

Time frame:
Baseline, Week 16 and Week 32
Reported as:
Mean · scores on a scale
Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)
scores on a scaleAIN457 300 mg Q4W - TP 1 and TP 2 -LPP CohortPlacebo - TP 1 - LPP CohortPlacebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort
Baseline n=24,13,1255.75 ± 16.47654.01 ± 23.25254.01 ± 23.252
Week 16 n=24,13,121.86 ± 10.695-6.94 ± 11.508-6.94 ± 11.508
Week 32 n=24,0,11-4.26 ± 12.876—-14.43 ± 16.464

Adverse events

Collected over Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300 mg Q4W - CLP Cohort0/25 (0%)0/25 (0%)15/25 (60%)
Placebo - CLP Cohort0/12 (0%)1/12 (8.3%)7/12 (58.3%)
Any AIN457 300 mg - CLP Cohort0/33 (0%)0/33 (0%)21/33 (63.6%)
Placebo to AIN457 300 mg Q2W - CLP Cohort0/8 (0%)0/8 (0%)6/8 (75%)
AIN457 300 mg Q4W - MLP Cohort0/24 (0%)1/24 (4.2%)18/24 (75%)
Placebo - MLP Cohort0/13 (0%)0/13 (0%)8/13 (61.5%)
Any AIN457 300 mg - MLP Cohort0/35 (0%)2/35 (5.7%)26/35 (74.3%)
Placebo to AIN457 300 mg Q2W - MLP Cohort0/11 (0%)1/11 (9.1%)8/11 (72.7%)
AIN457 300 mg Q4W - LPP Cohort0/24 (0%)0/24 (0%)16/24 (66.7%)
Placebo - LPP Cohort0/13 (0%)1/13 (7.7%)7/13 (53.8%)
Any AIN457 300 mg - LPP Cohort0/36 (0%)1/36 (2.8%)22/36 (61.1%)
Placebo to AIN457 300 mg Q2W - LPP Cohort0/12 (0%)1/12 (8.3%)6/12 (50%)
Most frequent serious events
Most frequent serious events
EventAIN457 300 mg Q4W - CLP CohortPlacebo - CLP CohortAny AIN457 300 mg - CLP CohortPlacebo to AIN457 300 mg Q2W - CLP CohortAIN457 300 mg Q4W - MLP CohortPlacebo - MLP CohortAny AIN457 300 mg - MLP CohortPlacebo to AIN457 300 mg Q2W - MLP CohortAIN457 300 mg Q4W - LPP CohortPlacebo - LPP CohortAny AIN457 300 mg - LPP CohortPlacebo to AIN457 300 mg Q2W - LPP Cohort
OsteoarthritisMusculoskeletal and connective tissue disorders0/250/120/330/80/240/131/351/110/240/130/360/12
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/251/120/330/80/240/130/350/110/240/130/360/12
NeuralgiaNervous system disorders0/250/120/330/80/240/130/350/110/240/131/361/12
Angina pectorisCardiac disorders0/250/120/330/80/240/130/350/110/241/130/360/12
Colitis ulcerativeGastrointestinal disorders0/250/120/330/81/240/131/350/110/240/130/360/12
PleurisyRespiratory, thoracic and mediastinal disorders0/250/120/330/81/240/131/350/110/240/130/360/12
Most frequent other events
Showing 10 of 78
Most frequent other events
EventAIN457 300 mg Q4W - CLP CohortPlacebo - CLP CohortAny AIN457 300 mg - CLP CohortPlacebo to AIN457 300 mg Q2W - CLP CohortAIN457 300 mg Q4W - MLP CohortPlacebo - MLP CohortAny AIN457 300 mg - MLP CohortPlacebo to AIN457 300 mg Q2W - MLP CohortAIN457 300 mg Q4W - LPP CohortPlacebo - LPP CohortAny AIN457 300 mg - LPP CohortPlacebo to AIN457 300 mg Q2W - LPP Cohort
HeadacheNervous system disorders3/250/123/330/80/241/132/352/115/242/135/360/12
Abdominal painGastrointestinal disorders0/250/120/330/80/241/132/352/110/240/130/360/12
DiarrhoeaGastrointestinal disorders2/250/123/331/81/240/133/352/110/240/130/360/12
COVID-19Infections and infestations1/250/122/331/82/240/134/352/110/241/130/360/12
Lichen planusSkin and subcutaneous tissue disorders3/251/124/331/84/240/135/351/111/240/132/361/12
HypertensionVascular disorders2/250/122/330/81/241/131/350/111/242/132/361/12
AstheniaGeneral disorders0/251/121/331/80/240/130/350/111/240/131/360/12
Fungal skin infectionInfections and infestations0/250/121/331/80/240/130/350/110/240/130/360/12
Post-acute COVID-19 syndromeInfections and infestations0/250/121/331/80/240/130/350/110/240/130/360/12
SuperinfectionInfections and infestations0/251/121/331/80/240/130/350/110/240/130/360/12

Baseline characteristics

Age, Customized
Age, Customized(Participants)AIN457 300 mg Q4W - TP 1 - CLP CohortPlacebo - TP 1 - CLP CohortAIN457 300 mg Q4W - TP 1 - MLP CohortPlacebo - TP 1 - MLP CohortAIN457 300 mg Q4W - TP 1 - LPP CohortPlacebo - TP 1 - LPP CohortTotal
18 to <65 years229148191284
> or = 65 years331055127
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 300 mg Q4W - TP 1 - CLP CohortPlacebo - TP 1 - CLP CohortAIN457 300 mg Q4W - TP 1 - MLP CohortPlacebo - TP 1 - MLP CohortAIN457 300 mg Q4W - TP 1 - LPP CohortPlacebo - TP 1 - LPP CohortTotal
Female1581412201079
Male1041014332
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 300 mg Q4W - TP 1 - CLP CohortPlacebo - TP 1 - CLP CohortAIN457 300 mg Q4W - TP 1 - MLP CohortPlacebo - TP 1 - MLP CohortAIN457 300 mg Q4W - TP 1 - LPP CohortPlacebo - TP 1 - LPP CohortTotal
Asian (Indian)0020002
Black or African American64211014
White1981912231394
White, American Indian or Alaska Native0010001
Baseline of Investigator's Global Assessment (IGA)
Baseline of Investigator's Global Assessment (IGA)(Participants)AIN457 300 mg Q4W - TP 1 - CLP CohortPlacebo - TP 1 - CLP CohortAIN457 300 mg Q4W - TP 1 - MLP CohortPlacebo - TP 1 - MLP CohortAIN457 300 mg Q4W - TP 1 - LPP CohortPlacebo - TP 1 - LPP CohortTotal
0=Clear0000000
1=Minimal1000001
2=Mild0000000
3=Moderate169228171082
4=Severe83257328
08

Study locations

35 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35233, United States
  • Novartis Investigative Site
    Thousand Oaks, California 91320, United States
  • Novartis Investigative Site
    Cromwell, Connecticut 06416, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32224, United States
  • Novartis Investigative Site
    Miami, Florida 33125, United States
  • Novartis Investigative Site
    Snellville, Georgia 30078, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68144, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89128, United States
  • Novartis Investigative Site
    East Windsor, New Jersey 08520, United States
  • Novartis Investigative Site
    Forest Hills, New York 11375, United States
  • Novartis Investigative Site
    New York, New York 10025 1737, United States
  • Novartis Investigative Site
    Portland, Oregon 97223, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29407, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Pflugerville, Texas 78660, United States
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Chambray les Tours, 37170, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Marseille Cedex 05, 13885, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Paris Cedex 10, 75475, France
  • Novartis Investigative Site
    Rouen Cedex, 76031, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bramsche, 49565, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Halle, 06120, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Luebeck, 23538, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
09

References and documents

Publications

  • Miteva M, Nadji M, Billero V, LaSenna C, Nattkemper L, Romanelli P. IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris. Am J Dermatopathol. 2022 Dec 1;44(12):874-878. doi: 10.1097/DAD.0000000000002316. Epub 2022 Sep 27. PubMed 36197049 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2021, 15 months.

Results were first posted in Aug 2023, 1 year 9 months after primary completion. A results delay was requested in Jan 2022.

Of 16 phase 2 interventional studies under Lichen Planus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 15 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2020
First posted
Mar 9, 2020
StartActual
Jul 27, 2020
Primary completionActual
Nov 16, 2021
CompletionActual
May 3, 2022
Results delay requested
Jan 18, 2022
Results first posted
Aug 22, 2023
Last update
Aug 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04300296
Responsible party
Sponsor
First posted
Mar 9, 2020
Start date
Jul 27, 2020
Primary completion
Nov 16, 2021
Completion
May 3, 2022
Results posted
Aug 22, 2023
Last update
Aug 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion